Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)

被引：0
|
作者：
Iwamoto, M. [1 ]
Matsutani, A. [1 ]
Ikari, A. [1 ]
Tominaga, T. [1 ]
Maezawa, S. [1 ]
Oku, H. [1 ]
Kimura, K. [1 ]
机构：
[1] Osaka Med Coll, Breast Surg, Osaka, Japan
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P086
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] A phase 2 study of de-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low risk pure HER2 breast cancer
    Tanaka, Satoru
    Morishima, Hirotaka
    Oda, Naofumi
    Matsunami, Nobuki
    Takashima, Tsutomu
    Noda, Satoru
    Kashiwagi, Shinichiro
    Tauchi, Yukie
    Asano, Yuka
    Kimura, Kosei
    Fujioka, Hiruya
    Terasawa, Risa
    Kawaguchi, Kanako
    Ikari, Ayana
    Morimoto, Takashi
    Michishita, Shintaro
    Kobayashi, Toshihiro
    Sakane, Junna
    Nitta, Toshikatsu
    Sato, Nayuko
    Hokimoto, Norihiro
    Nishida, Yukihiro
    Iwamoto, Mitsuhiko
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Phase II study of neoadjuvant weekly albumin-bound paclitaxel for node-positive breast cancer
    Hattori, A.
    Hirano, A.
    Ogura, K.
    Inoue, H.
    Okubo, F.
    Miyamoto, R.
    Jibiki, N.
    Fujibayashi, M.
    Shimizu, T.
    BREAST, 2015, 24 : S92 - S92
  • [23] De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer
    Satoru Tanaka
    Nobuki Matsunami
    Hirotaka Morishima
    Naofumi Oda
    Tsutomu Takashima
    Satoru Noda
    Shinichiro Kashiwagi
    Yukie Tauchi
    Yuka Asano
    Kosei Kimura
    Hiroya Fujioka
    Risa Terasawa
    Kanako Kawaguchi
    Ayana Ikari
    Takashi Morimoto
    Shintaro Michishita
    Toshihiro Kobayashi
    Junna Sakane
    Toshikatsu Nitta
    Nayuko Sato
    Norihiro Hokimoto
    Yukihiro Nishida
    Mitsuhiko Iwamoto
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1099 - 1104
  • [24] De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer
    Tanaka, Satoru
    Matsunami, Nobuki
    Morishima, Hirotaka
    Oda, Naofumi
    Takashima, Tsutomu
    Noda, Satoru
    Kashiwagi, Shinichiro
    Tauchi, Yukie
    Asano, Yuka
    Kimura, Kosei
    Fujioka, Hiroya
    Terasawa, Risa
    Kawaguchi, Kanako
    Ikari, Ayana
    Morimoto, Takashi
    Michishita, Shintaro
    Kobayashi, Toshihiro
    Sakane, Junna
    Nitta, Toshikatsu
    Sato, Nayuko
    Hokimoto, Norihiro
    Nishida, Yukihiro
    Iwamoto, Mitsuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1099 - 1104
  • [25] Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2
    Masuda, N.
    Ando, M.
    Aogi, K.
    Ino, H.
    Iwata, H.
    Tokuda, Y.
    Nakamura, S.
    Yamamoto, N.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] A phase II neoadjuvant trial of sequential triweekly nanoparticle albumin-bound paclitaxel and cyclophosphamide followed by 5-fluorouracil/epirubicin/cyclophosphamide in the treatment of operable breast cancer.
    Masumoto, Norio
    Kadoya, Takayuki
    Amioka, Ai
    Kajitani, Keiko
    Emi, Akiko
    Shigematsu, Hideo
    Haruta, Rumi
    Kataoka, Tsuyoshi
    Matsuura, Kazuo
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
    Conte, Benedetta
    Montemurro, Filippo
    Levaggi, Alessia
    Blondeaux, Eva
    Molinelli, Chiara
    Cardinali, Barbara
    Poggio, Francesca
    Buzzatti, Giulia
    Bighin, Claudia
    Lambertini, Matteo
    Del Mastro, Lucia
    TUMORI JOURNAL, 2023, 109 (01): : 71 - 78
  • [28] Nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in neoadjuvant chemotherapy for resectable breast cancer: Phase II trial
    Kin, T.
    Fujihara, M.
    Yoshimura, Y.
    Kajiwara, Y.
    Ito, M.
    Ohtani, S.
    Taniguchi, K.
    Morito, T.
    Takada, S.
    Ichimura, K.
    BREAST, 2017, 32 : S79 - S80
  • [29] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [30] Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer
    Yao, Lu
    Zhang, Juan
    Liu, Yiqiang
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (06) : 553 - 561
12345